A comprehensive analysis of millions of FDA adverse event reports has revealed that Wegovy, the widely prescribed weight-loss medication, may carry an elevated risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition often called “eye stroke” that can cause sudden, permanent vision loss. The findings show a risk signal nearly five times stronger for Wegovy compared to Ozempic, despite both medications containing the same active ingredient, semaglutide.
Reported Eye Stroke Cases by Semaglutide Formulation
NAION reports per million prescriptions, FDA Adverse Event Reporting System 2020-2024
Source: FDA FAERS Database Analysis, 2024 | Georgian Medical Journal News
Higher Doses May Drive Increased Risk
The disparity between Wegovy and Ozempic appears linked to dosing differences. Wegovy is prescribed at higher doses (up to 2.4mg weekly) for weight management, while Ozempic typically uses lower doses (0.5-1mg weekly) for diabetes control.
NAION occurs when blood flow to the optic nerve is suddenly blocked and can cause irreversible vision loss in the affected eye within hours to days. The condition affects approximately 2-10 people per 100,000 annually in the general population, according to data from the National Institutes of Health.
FDA Database Reveals Pattern Across Millions of Reports
The analysis examined over 15 million adverse event reports submitted to the FDA between 2020 and 2024, focusing on the 847 cases of NAION reported during this period. For Wegovy, the reporting odds ratio for NAION was 4.84 times higher than for Ozempic, even after adjusting for the total number of adverse events reported for each drug.
NAION reports typically occurred within the first six months of starting semaglutide treatment, with a median time to onset of 14 weeks for both formulations. Most patients who experienced NAION were over 50 years old and had pre-existing cardiovascular risk factors.
Clinical Context and Existing Risk Factors
NAION has established associations with diabetes, hypertension, and sleep apnea – conditions that often overlap with the patient populations prescribed GLP-1 receptor agonists like semaglutide. However, the dose-dependent pattern observed between Wegovy and Ozempic suggests a potential causal relationship beyond these underlying comorbidities.
The mechanism by which semaglutide might increase NAION risk remains unclear, though researchers hypothesize it could relate to the drug’s effects on blood pressure, blood sugar fluctuations, or vascular function.
Regulatory Response and Clinical Recommendations
While the FDA has not yet issued formal guidance changes based on these findings, the agency continues to monitor post-market safety data for all GLP-1 receptor agonists. European regulators have similarly maintained their current prescribing recommendations while evaluating emerging safety signals.
The analysis also examined other GLP-1 receptor agonists including liraglutide and dulaglutide, finding lower but still elevated NAION reporting rates compared to non-GLP-1 diabetes medications. This class-wide pattern suggests the association may extend beyond semaglutide specifically.
The reporting odds ratio for NAION was 4.84 times higher for Wegovy compared to Ozempic, suggesting a dose-dependent relationship that cannot be explained by differential reporting patterns alone.
— FDA Adverse Event Reporting System Analysis (2024)
Key takeaways
- Wegovy shows 5x higher eye stroke risk signal than Ozempic despite identical active ingredient
- Higher dosing for weight loss (2.4mg) may drive increased risk compared to diabetes doses
- NAION typically occurs within first 6 months of treatment, causing permanent vision loss
- Patients should be counseled about sudden vision changes and seek immediate care if symptoms occur
Frequently asked questions
What is NAION or “eye stroke”?
Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when blood flow to the optic nerve is suddenly blocked, causing rapid and usually permanent vision loss in the affected eye. It typically affects people over 50 with cardiovascular risk factors.
Should I stop taking Wegovy if I’m concerned about vision problems?
Do not stop prescribed medications without consulting your healthcare provider. Discuss your individual risk factors and any vision concerns with your doctor, who can help weigh the benefits and risks based on your specific situation.
How can I recognize symptoms of an eye stroke?
NAION typically causes sudden, painless vision loss in one eye, often described as a curtain or shadow blocking part of the visual field. Any sudden vision changes require immediate medical evaluation, as prompt treatment may help preserve remaining vision.
As regulatory agencies continue evaluating these safety signals, healthcare providers and patients must balance the proven cardiovascular and metabolic benefits of semaglutide against emerging risks like NAION.
Source: Wegovy linked to rare “eye stroke” that can cause sudden blindness
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
